September 9, 2024 01:47 PM EDTUpdated 02:03 PM

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

Lei Lei Wu

News Reporter

Max Gelman

Senior Editor

AstraZeneca is focusing on a subgroup of lung cancer patients as it seeks a path to approval for its TROP2-directed antibody-drug conjugate, which earlier this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

Lei Lei Wu

News Reporter

Max Gelman

Senior Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

As­traZeneca, Gilead de­tail TROP2 ADC da­ta in lung can­cer as they search for new ways for­ward

News Reporter

Senior Editor

Sign up to read this article for free.

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward